Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.620
+0.050 (3.18%)
Oct 28, 2026, 4:00 PM EDT - Market closed
Inhibikase Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
35
Market Cap
294.96M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 260.50K | 137.06K | 111.03% |
| Dec 31, 2022 | 123.44K | -2.98M | -96.02% |
| Dec 31, 2021 | 3.10M | 2.40M | 343.92% |
| Dec 31, 2020 | 698.47K | -424.27K | -37.79% |
| Dec 31, 2019 | 1.12M | -2.92M | -72.22% |
| Dec 31, 2018 | 4.04M | 1.98M | 96.07% |
| Dec 31, 2017 | 2.06M | 1.09M | 113.04% |
| Dec 31, 2016 | 967.39K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Century Therapeutics | 109.16M |
| Fulcrum Therapeutics | 80.00M |
| Bicycle Therapeutics | 61.21M |
| vTv Therapeutics | 36.84M |
| Opus Genetics | 9.86M |
| Vicore Pharma Holding AB | 412.09K |
| SAB Biotherapeutics | 114.70K |
IKT News
- 1 day ago - Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026 - GlobeNewsWire
- 8 days ago - Inhibikase Therapeutics appoints Kailera CMO Scott Wasserman to board - TheFly
- 8 days ago - Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors - GlobeNewsWire
- 15 days ago - Inhibikase Therapeutics initiated with a Neutral at Chardan - TheFly
- 26 days ago - Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Inhibikase Therapeutics Slides: Corporate presentation - Filings
- 2 months ago - Inhibikase Therapeutics reports Q2 EPS (11c), consensus (9c) - TheFly
- 2 months ago - Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity - GlobeNewsWire